Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

The stock's rise snapped a four-day losing streak.

BofA reinstated coverage of Biogen (BIIB) with a Neutral rating and $178 price target Biogen is “a cheaper name,” mostly ...

CPI data matched expectations; Goods inflation rose to its highest level since May 2023. Albertson’s terminates merger with ...

Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel, targeted, small molecule cancer ...

Wall Street trading got off to a mixed start on Wednesday as investors digested last month's all-important CPI reading.